Abstract
Molecular Psychiatry, August 2020: new impact factor, and highlights of recent advances in psychiatry, including an overview of the brain\u2019s response to stress during infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Highlights
This year we published four special issues, one on schizophrenia [1–19], one on stress and behavior [20–38], and two on depression, in June [39–55] and July [56–76]
Dempster et al present a 7-T magnetic resonance spectroscopic study of glutathione and glutamate showing early treatment response in first-episode psychosis [82]; Niculescu et al present intriguing work on blood biomarkers for memory that can be targeted toward early detection of risk for Alzheimer’s disease (AD), pharmacogenomics, and repurposed drugs [83], and Polimanti et al leverage genome-wide data to investigate differences between opioid use versus opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium [84]
In other original research articles, we present key new advances across multiple fields
Summary
This year we published four special issues, one on schizophrenia [1–19], one on stress and behavior [20–38], and two on depression, in June [39–55] and July [56–76]. [79] These exciting Perspectives are followed by three important Reviews: by Prieto et al on post-translational modifications of the Fragile X Mental Retardation Protein in neuronal function and dysfunction; by Rogdaki et al, a meta-analysis of the magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome [80], and by Smigielski et al, a systematic review of empirical human findings on the epigenetic mechanisms in schizophrenia and other psychotic disorders [81].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
